Core Insights - Cumberland Pharmaceuticals has announced that its Caldolor (ibuprofen) Injection is now associated with a permanent J-code (J1741) and a reimbursement price, providing a CMS-covered non-opioid option for pain and fever management [1][2][5] Group 1: Product Update - Caldolor is now linked to an established reimbursement price, allowing healthcare providers to access a reimbursable non-opioid alternative for pain management [3] - The product is indicated for managing mild to moderate pain and as an adjunct for moderate to severe pain, as well as for fever reduction [4] Group 2: Industry Context - The introduction of Caldolor as a non-opioid alternative is significant in the context of the ongoing opioid crisis, supporting safer pain management strategies [2] - The update aligns with opioid-sparing initiatives, helping healthcare providers make clinically appropriate decisions [3] Group 3: Company Overview - Cumberland Pharmaceuticals is the largest biopharmaceutical company based in Tennessee, focusing on unique products that enhance patient care [5] - The company’s portfolio includes several FDA-approved products, with Caldolor being a key offering [6]